您的位置: 首页 > 农业专利 > 详情页

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
专利权人:
ROCHE GLYCART AG
发明人:
UMANA PABLO,JEAN-MAIRET JOEL,BAILEY JAMES E (DECEASED) REPRESENTED BY BAILEY SEAN -,BAILEY SEAN
申请号:
NZ60311102
公开号:
NZ603111A
申请日:
2002.08.05
申请国别(地区):
NZ
年份:
2014
代理人:
摘要:
Disclosed is a glycoengineered antibody that specifically binds the human CD20 antigen, wherein said antibody has a decreased proportion of non-bisected complex oligosaccharides having the m/z value of 1486 Daltons and an increased proportion of bisected hybrid or galactosylated complex oligosaccharides having the m/z values of 1664, 1810, and 1826 Daltons relative to a corresponding, non-glycoengineered anti-CD20 antibody, and wherein the glycoengineered antibody reaches the maximal ADCC activity of the corresponding non-glycoengineered anti-CD20 antibody at an antibody concentration that is approximately five to ten-fold lower as a result of the glycoengineering.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充